Orion Corporation: Managers’ transactions – Agendum Oy

ORION CORPORATION
MANAGERS’ TRANSACTIONS
11 MAY 2023 at 15.30 EEST
        

Orion Corporation: Managers’ transactions – Agendum Oy

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj – Managers’ Transactions
____________________________________________
Person subject to the notification requirement
Name: Agendum Oy
Position: Closely associated person
(X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer
Name: Mikael Silvennoinen
Position: Member of the Board
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 31439/4/6

____________________________________________
Transaction date: 2023-05-09
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 85 Unit price: 43.22 EUR
(2): Volume: 36 Unit price: 43.22 EUR
(3): Volume: 151 Unit price: 43.22 EUR
(4): Volume: 151 Unit price: 43.22 EUR
(5): Volume: 175 Unit price: 43.22 EUR
(6): Volume: 120 Unit price: 43.21 EUR
(7): Volume: 151 Unit price: 43.21 EUR
(8): Volume: 63 Unit price: 43.21 EUR
(9): Volume: 175 Unit price: 43.21 EUR
(10): Volume: 2 Unit price: 43.19 EUR

Aggregated transactions (10):
Volume: 1109 Volume weighted average price: 43.21536 EUR
____________________________________________
Transaction date: 2023-05-09
Venue: TQEX
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 38 Unit price: 43.21 EUR

Aggregated transactions (1):
Volume: 38 Volume weighted average price: 43.21 EUR
____________________________________________
Transaction date: 2023-05-09
Venue: CEUX
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 21 Unit price: 43.21 EUR
(2): Volume: 154 Unit price: 43.21 EUR
(3): Volume: 21 Unit price: 43.2 EUR
(4): Volume: 154 Unit price: 43.2 EUR
(5): Volume: 30 Unit price: 43.19 EUR

Aggregated transactions (5):
Volume: 380 Volume weighted average price: 43.20382 EUR
____________________________________________
Transaction date: 2023-05-09
Venue: AQEU
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 125 Unit price: 43.22 EUR
(2): Volume: 107 Unit price: 43.2 EUR

Aggregated transactions (2):
Volume: 232 Volume weighted average price: 43.21078 EUR

Orion Corporation

Liisa Hurme

President and CEO

    Olli Huotari

SVP, Corporate Functions

 

                                                

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion’s net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.

Staff

Recent Posts

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

45 minutes ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

15 hours ago

Best GLP-1 Weight Loss Shot (2026): Direct Meds Reviews Prescription Access Pathways as New GLP-1 Formats Expand

LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…

18 hours ago

Nutri Derma Guard Skin Tag Remover Ingredients Investigated: 2026 Analysis Examines Formulation And Consumer Disclosures

Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…

18 hours ago

SleepZee Mouth Guard Legitimacy Examined: 2026 Consumer Analysis Investigates Anti-Snoring Device Claims and Company Transparency

Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…

18 hours ago